LRI Investments LLC decreased its holdings in Eli Lilly and Company (NYSE:LLY - Free Report) by 31.0% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,129 shares of the company's stock after selling 958 shares during the quarter. LRI Investments LLC's holdings in Eli Lilly and Company were worth $1,758,000 as of its most recent filing with the SEC.
Several other institutional investors have also modified their holdings of the business. WestEnd Advisors LLC raised its stake in Eli Lilly and Company by 210.0% during the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after buying an additional 21 shares in the last quarter. Citizens National Bank Trust Department raised its stake in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after buying an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the first quarter valued at approximately $40,000. Mascagni Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the fourth quarter valued at approximately $43,000. Finally, O Brien Wealth Partners LLC raised its stake in Eli Lilly and Company by 25.5% during the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock valued at $49,000 after buying an additional 12 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.
Eli Lilly and Company Stock Performance
LLY traded up $2.69 during trading hours on Friday, hitting $793.34. The company's stock had a trading volume of 2,851,585 shares, compared to its average volume of 3,675,715. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18. The firm has a market capitalization of $751.88 billion, a PE ratio of 64.55, a PEG ratio of 1.16 and a beta of 0.40. The company has a 50-day simple moving average of $766.39 and a 200 day simple moving average of $800.02.
Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter last year, the business posted $2.58 earnings per share. The firm's revenue for the quarter was up 45.2% compared to the same quarter last year. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 EPS for the current year.
Eli Lilly and Company Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a dividend yield of 0.76%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio is presently 48.82%.
Analyst Ratings Changes
Several analysts have issued reports on LLY shares. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the company from $892.00 to $888.00 in a research note on Tuesday, April 8th. UBS Group lowered their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a report on Friday, May 2nd. Wall Street Zen cut Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Saturday, June 28th. Morgan Stanley reiterated an "overweight" rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research report on Thursday. Finally, Guggenheim increased their price target on Eli Lilly and Company from $936.00 to $942.00 and gave the stock a "buy" rating in a research report on Friday. One research analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,012.56.
Read Our Latest Analysis on Eli Lilly and Company
Eli Lilly and Company Profile
(
Free Report)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Stories

Before you consider Eli Lilly and Company, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.
While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.